Vimian (Buy, TP: SEK110.00) - 2022 likely off to a good start
We believe Vimian’s 2022 got off to a good start, with a healthy underlying trend in the most important business areas as well as an active M&A agenda. In the Q1 report (due at 07:45 CET on 24 May), we will focus on the trends in the MedTech operations, and its annual stocking programme, and in the Specialty Pharma division. We reiterate our BUY and SEK110 target price.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.